TRABER PETER G
Known title: Chief Medical OfficerCIK: 0001284500
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Lisata reports first patient dose in MAR002 acromegaly trial. Lisata Therapeutics announced that its subsidiary Marea Therapeutics has given the first dose of MAR002 to a patient in a Phase 2 trial for acromegaly. This marks the first clinical exposure of the drug and represents a key step toward potential regulatory approval. The announcement highlights progress in Lisata’s development pipeline, though the company remains in early stages of product development.
Transaction History
| RNAC | ▼ Sell | Open Market | 705 | $747 | 9/25/2023 | View on chart |
| RNAC | ▼ Sell | Open Market | 3,445 | $4K | 1/5/2023 | View on chart |
| RNAC | ▼ Sell | Open Market | 20 | $22 | 1/5/2023 | View on chart |
| RNAC | ▼ Sell | Open Market | 8,164 | $9K | 1/4/2023 | View on chart |
| RNAC | ▼ Sell | Open Market | 15 | $17 | 1/4/2023 | View on chart |
| RNAC | ▲ Buy | Grant | 200,000 | $0 | 1/2/2023 | View on chart |
| LSTA | ▲ Buy | Grant | 65,430 | $0 | 1/10/2022 | View on chart |
| RNAC | ▼ Sell | Open Market | 3,226 | $10K | 1/5/2022 | View on chart |
| RNAC | ▲ Buy | Grant | 90,200 | $0 | 1/3/2022 | View on chart |
| RNAC | ▼ Sell | Open Market | 4,083 | $12K | 12/10/2021 | View on chart |
| RNAC | ▲ Buy | Grant | 13,750 | $0 | 12/8/2021 | View on chart |
| RNAC | ▼ Sell | Open Market | 3,636 | $16K | 10/13/2021 | View on chart |
| RNAC | ▲ Buy | Grant | 13,750 | $0 | 10/1/2021 | View on chart |
| RNAC | ▲ Buy | Grant | 9,100 | $0 | 9/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session
Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session. Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.